Drug Profile
Research programme: kidney disease therapeutics - AstraZeneca/Evotec SE
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer AstraZeneca; Evotec SE
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Kidney disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Kidney-disorders in Germany
- 21 Oct 2013 Early research in Kidney disorders in Germany (unspecified route)